Summary
a2 Milk Company launched two ultra-premium infant formula products in New Zealand on 8 October 2026 — ZhiChu Qirun and ZhiChu Zhichun — which are set to enter the Chinese market, expanding the a2 ZhiChu new national standard product range. Both products use A2 milk sourced under a2's uniform standard, containing only A2 beta-casein, and are produced at a2's Pokeno plant on New Zealand's North Island. a2 completed a 100% acquisition of the plant for approximately NZ$282 million in August 2025 and invested about NZ$100 million in capacity expansion and upgrades.
Bai Wenxi, chief economist for China at the China Enterprise Capital Alliance, said the move achieves production autonomy, with designed annual capacity of tens of millions of cans, and expands the registered product line from one to three. ZhiChu Qirun is a2's first dual-patent product, with a formula built around three maternal-nutrition dimensions: protein, lipids and oligosaccharides. ZhiChu Zhichun is a2's first organic A2 protein formula, sourced from New Zealand organic grass-fed farms and holding dual organic certification in China and New Zealand.
a2 managing director and CEO David Bortolussi said the Chinese market remains central to a2's strategy and the two products represent another breakthrough in its core infant formula category.
Commentary
a2 Milk Company's launch of two ultra-premium infant formula products marks a key step in deepening its China strategy. As a pioneer in the A2 protein segment, a2 has secured a position in the ultra-premium market through first-mover advantage and research. But China's infant formula market has been contracting in recent years and competition has intensified.
Local brands such as Feihe and Yili are pushing premiumisation, while foreign brands including Wyeth and Mead Johnson are accelerating localisation, putting pressure on a2. By acquiring the Pokeno plant for production autonomy and launching organic A2 and dual-patent products, a2 aims to strengthen its differentiation and defend its position in China's ultra-premium segment. For New Zealand SMEs, a2's move highlights continued Chinese demand for high-quality, functional dairy products, especially those with unique selling points such as A2 protein and organic certification, which still command a premium.
However, China's infant formula registration regime is stringent and supply chains are increasingly localised. NZ companies seeking entry need to invest more in formula innovation, brand trust and channel partnerships. The barriers a2 has built through its own plant and dual organic certification also suggest NZ dairy firms should prioritise vertical integration and certification credentials to meet China's tightening regulation and competition.
Keywords: a2 Milk Company, ultra-premium infant formula, ZhiChu Qirun, ZhiChu Zhichun, Pokeno plant, A2 protein, organic certification, Chinese market
Source: Wealth Account
Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.
